Beckman Coulter’s facility in Lismeehan, County Clare, Ireland produces state-of-the-art in-vitro diagnostic devices while stewarding a historic property that is home to ancient landmarks. Since we last reported on this site in 2015, the site:
Beckman Coulter’s facility in Mishima Japan sits at the base of Mount Fuji. Recognizing its unique place in the local ecosystem, the Mishima team leverages DBS to operate under a stringent environmental management system using our Visual Management and Kaizen tools, this team has:
2019 – Beckman Coulter awarded BARDA funding to develop novel sepsis algorithm.
The contract will enable Beckman Coulter, in collaboration with Dascena, Inc, to develop and commercialize a novel machine-learning-based sepsis detection algorithm. By combining novel laboratory test parameter values with electronic health record information, the objective for this next-generation analytic algorithm will be to accurately predict and detect sepsis earlier, with the goals of reducing sepsis mortality through earlier intervention and reducing the total cost of care.
2019 - SelectScience® Scientist's Choice Award: Best New Clinical Instrument (DxH 520)
2019 - MD Buyline Ratings
Our key hematology initiative has been improving quality and reliability for our customers, and the results speak for themselves in our third-party data scores.
2020 – Frost & Sullivan’s Global New Product Innovation Award: Hematology testing market (DxH 690T)
2020 – Beckman Coulter awarded expanded partnership with BARDA to assess sepsis diagnostic and prediction algorithm with COVID-19 patients.
The partnership was awarded to Beckman Coulter, in collaboration with Dascena, Inc., for additional advanced research and development toward optimization of a machine-learning based sepsis diagnostic and prediction algorithm to include assessing its use with coronavirus (COVID-19) patients.
Urinalysis
English
